Phaseline

Targets › S1PR1

S1PR1 (Sphingosine 1-phosphate receptor 1): drug programs, companies and trials

10 programs from 9 companies in 26 trials: 11 Phase 3, 10 Phase 2, 4 Phase 4, 1 Phase 1; Immunology, Neurology, Oncology; next expected readout Dec 2026.

G protein-coupled receptor for the bioactive lysosphingolipid sphingosine 1-phosphate (S1P) that seems to be coupled to the G(i) subclass of heteromeric G proteins. Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. (UniProt, P21453)

Open in Phaseline: the race on S1PR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisFingolimod
Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent
S1PR5, S1PR2, S1PR4, S1PR3, S1PR1Phase 4Multiple Sclerosis; Diabetes Mellitus, Type 2; Non Small Cell Lung CancerSep 2027
Bristol-Myers SquibbOzanimod
Sphingosine 1-phosphate receptor Edg-1 modulator; Sphingosine 1-phosphate receptor 5 modulator
S1PR1, S1PR5Phase 4Relapsing Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Colitis, Ulcerative; Alzheimer DiseaseDec 2028
Viatris InnovationCenerimod
Sphingosine 1-phosphate receptor Edg-1 modulator
S1PR1Phase 3Lupus Erythematosus, Systemic; Nephritis, LupusDec 2026
Priothera SASmocravimod
Sphingosine 1-phosphate receptor Edg-1 agonist
S1PR1Phase 3Adult Acute Myeloid LeukemiaMay 2027
Boehringer IngelheimBI 764198
Sphingosine-1-phosphate receptor modulator
S1PR1Phase 3Focal Segmental Glomerulosclerosis; Proteinuric Kidney DiseasesJan 2028
Vanda PharmaceuticalsPonesimod
Sphingosine 1-phosphate receptor Edg-1 agonist
S1PR1Phase 3Moderate-to-severe Chronic Plaque Psoriasis; Ulcerative Colitis (UC)Aug 2028
PfizerEtrasimod
Sphingosine 1-phosphate receptor Edg-1 agonist; Sphingosine 1-phosphate receptor Edg-6 modulator; Sphingosine 1-phosphate receptor Edg-1 modulator
S1PR1, S1PR4, S1PR5Phase 3Ulcerative Colitis; Colitis, Ulcerative; Healthy Participant; PouchitisJun 2029
NovartisSiponimod
Sphingosine 1-phosphate receptor Edg-1 agonist
S1PR1Phase 3Multiple Sclerosis (MS); Alzheimer DiseaseFeb 2031
Aptabio TherapeuticsIsuzinaxib
Sphingosine-1-phosphate receptor 1 (S1PR1) modulator
S1PR1Phase 2Diabetic Kidney Disease (DKD)Jun 2027
Washington University School of Medicine[C-11]-CS1P1
S1P1 PET imaging agent
S1PR1Phase 2Central Nervous System CancerJun 2031

Conditions

Lupus Erythematosus, Systemic (2) Alzheimer Disease (2) Relapsing Multiple Sclerosis (2) Colitis, Ulcerative (2) Ulcerative Colitis (2) Multiple Sclerosis (2) Nephritis, Lupus (1) Focal Segmental Glomerulosclerosis (1) Proteinuric Kidney Diseases (1) Moderate-to-severe Chronic Plaque Psoriasis (1) Ulcerative Colitis (UC) (1) Multiple Sclerosis (MS) (1)

Modalities

small molecule (9), mixed (1)

Companies

Novartis (2) Viatris Innovation (1) Boehringer Ingelheim (1) Vanda Pharmaceuticals (1) Bristol-Myers Squibb (1) Washington University School of Medicine (1) Pfizer (1) Priothera SAS (1) Aptabio Therapeutics (1)

Related targets

S1PR5 (3) S1PR4 (2) S1PR2 (1) S1PR3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.